Navigating the Non-Small Cell Lung Cancer Treatment Landscape: Unraveling Biomarkers, Emerging Therapies, and Resource Utilization Strategies

This activity was originally broadcast in conjunction with Asembia Specialty Pharmacy Summit 2024.

Program Description

Biomarker testing has become an essential component of the diagnostic and treatment approach in non-small cell lung cancer (NSCLC), helping pharmacists on the oncology care team make informed recommendations about treatment strategies. Epidermal growth factor receptor (EGFR) mutations are the most commonly observed mutations in patients with NSCLC. With multiple EGFR-targeted agents available and under investigation, the complexity of selecting an ideal EGFR inhibitor involves considerations like patient factors, disease specifics, toxicities, and sequencing, making specialty and oncology pharmacists crucial in optimizing patient care. Participants will review clinical and safety data for the EGFR inhibitors used as monotherapy and in combination regimens for the treatment of EGFR mutation-positive NSCLC. This session will also explore best practices for pharmacists to apply precision medicine and incorporate appropriate biomarker testing strategies into treatment paradigms for patients with NSCLC to facilitate timely and appropriate access to therapies and enhance patient care and outcomes.

Target audience: Oncology and specialty pharmacists

Type of activity: Application
Release date: May 17, 2024
Expiration date: May 17, 2025

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the importance of appropriate biomarker testing on patient safety, treatment outcomes, and overall cost of care
• Explore the clinical and safety evidence to support current recommendations and emerging treatments for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
• Identify approaches to optimize the value of biomarker testing, resource utilization, and patient outcomes in the management of EGFR mutation-positive NSCLC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-136-H01-P. The activity is available for CE credit through May 17, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Amanda S. Cass, PharmD, BCPS, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: G1 Therapeutics, Takeda, Regeneron, Daiichi Sankyo

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Jocelyn Mohs, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms